Opinion of some Brazilian rheumatologists about biosimilars

Revista Brasileira de Reumatologia

Volumn 51, Issue 6, 2011, Pages 662-671

  Azevedo, Valderilio Feijó ^a   Felippe, Lúcio Ricardo ^a   Machado, Denise Magalhães ^a  

^a FEDERAL UNIVERSITY OF PARANÁ   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL PRODUCT; ETANERCEPT; GENERIC DRUG; RITUXIMAB; BIOSIMILAR AGENT;

BIOCOMPATIBILITY; BIOEQUIVALENCE; BRAZIL; DRUG APPROVAL; DRUG EFFICACY; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; FEMALE; GOVERNMENT REGULATION; HUMAN; IMMUNOGENICITY; LETTER; MALE; PATENT; PATIENT SAFETY; PHYSICIAN ATTITUDE; PRESCRIPTION; QUESTIONNAIRE; RESIDENT; RHEUMATOLOGY; HEALTH PERSONNEL ATTITUDE;

ATTITUDE OF HEALTH PERSONNEL; BIOSIMILAR PHARMACEUTICALS; BRAZIL; FEMALE; HUMANS; MALE; QUESTIONNAIRES; RHEUMATOLOGY;

EID: 82955206455     PISSN: 04825004     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Letter

References (12)

1. Azevedo VF. Are we prepared to prescribe biosimilars? Rev Bras Reumatol 2010; 50(3):221-24.
2. Mellstedt H, Niederwieser D, Ludwig H. The challenge of biosimilars. Annals of Oncology 2008; 19:411-9.
3. Lanthier M, Behrman R, Nardinelli C. Economic issues with follow-on protein products. Nat Rev Drug Discov 2008; 7(9):733-7.
4. Schellekens H. Biosimilar therapeutics - what do we need to consider? NDT Plus 2009; 2(Suppl1):i27-i36.
5. Azevedo VF. Biossimilares - eles são iguais aos genéricos? Correio Braziliense, 25 de setembro de 2010.
6. Roger SD. Biosimilars: current status and future directions. Expert Opin Biol Ther 2010; 10(7):1011-8.
7. Roger SD, Mikhail A. Biosimilars: opportunity or cause for concern? J Pharm Pharm Sci 2007; 10(3):405-10.
8. ANVISA, Resolução de Diretoria Colegiada n° 315. 2005.
9. Herrero Ambrosio A. Biosimilars: regulatory status for approval. Farm Hosp 2010; 34S1:16-18.
10. Gottlieb S. Biosimilars: policy, clinical, and regulatory considerations. Am J Health Syst Pharm 2008; 65(14 Suppl 6):S2-8.
11. Roger SD, Goldsmith D. Biosimilars: it's not as simple as cost alone. J Clin Pharm Ther 2008; 33(5):459-64.
12. Nowicki M. Basic facts about biosimilars. Kidney Blood Press Res 2007; 30:267-72.